Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2024-04-28 Annual Report
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
益丰药房2023年年度报告（英文版）
Annual Report Classification · 100% confidence The document is titled '2023 Annual Report' and contains detailed sections typical of a full annual report, including company profile, financial indicators, management discussion and analysis, corporate governance, environmental and social responsibility, changes in shares and shareholders, bond information, and financial statements. It includes audited financial data, profit distribution plans, and risk statements. The presence of an unqualified audit report and signatures from responsible persons further confirms this is the full annual report document, not just an announcement or summary. The length of the document (15,000 characters) and the detailed content confirm it is not a brief announcement or certification. Therefore, the document is classified as an Annual Report (10-K). FY 2023
2024-04-28 Chinese
益丰药房审计委员会对2023年度会计师事务所履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Audit Committee of 益丰大药房连锁股份有限公司 regarding the supervision of the accounting firm 天健会计师事务所 for the fiscal year 2023. It details the audit firm's qualifications, the audit process, communication with management, and the committee's evaluation of the audit firm's performance and independence. The document does not contain the full annual financial statements or comprehensive financial data but rather focuses on the audit committee's oversight and evaluation of the external auditor's work. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of internal or regulatory oversight related to audits, excluding the full Annual Report. The document length is 2289 characters, which is relatively short but contains substantive content about audit supervision rather than just an announcement. Therefore, the appropriate classification is AR with high confidence. FY 2023
2024-04-28 Chinese
益丰药房第四届监事会第三十二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 32nd meeting of the 4th Supervisory Board of Yifeng Pharmacy Chain Co., Ltd. It includes multiple agenda items such as approval of the 2023 Supervisory Board Work Report, 2023 Annual Report and its summary, 2023 Financial Final Report, 2023 Fundraising Use Report, 2023 Internal Control Evaluation Report, 2023 Profit Distribution Plan, bank credit applications, guarantees for subsidiaries, use of idle funds for wealth management, repurchase and cancellation of restricted stock, confirmation of related party transactions, and approval of the 2024 Q1 report. The document is a formal announcement of meeting resolutions rather than the reports themselves. The length is under 5,000 characters, and it states that these reports have been prepared and approved but does not contain the full reports or detailed financial data. Therefore, it is not the Annual Report (10-K) or Interim Report (IR) itself, but an announcement of supervisory board meeting resolutions including approval of these reports. This fits best with Regulatory Filings (RNS) as it is a formal regulatory announcement of meeting decisions and approvals, not the reports themselves or a proxy solicitation or voting results announcement. Confidence is high due to the detailed meeting resolution format and absence of full report content.
2024-04-28 Chinese
益丰药房2023年年度报告
Annual Report Classification · 100% confidence The document is titled as a "2023 年年度报告" which translates to "2023 Annual Report". It contains detailed financial data, management discussion and analysis, company overview, financial statements, and audit opinions. The presence of a standard unqualified audit report from Tianjian Accounting Firm and signatures from company financial officers further confirms this is a full annual report. The document length is substantial (15,000 characters and more), and it includes comprehensive financial and operational information for the fiscal year 2023. Therefore, it fits the definition of an Annual Report (10-K). FY 2023
2024-04-28 Chinese
益丰药房关于续聘2024年会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (Tianjian CPA Firm) for auditing services for the fiscal year 2024. It details the firm's qualifications, audit fees, and the approval process by the board and audit committee. There is no actual audit report or financial statements included, only information about the appointment and related procedures. The document length is 3491 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this is not the audit report itself but an announcement about the audit firm appointment, fitting the category of Audit Report / Information (AR) since it relates to audit information but is not a full annual report or audit report document. FY 2024
2024-04-28 Chinese
益丰药房2023年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised through convertible bonds in the year 2023 by 益丰大药房连锁股份有限公司. It includes specifics on the amount raised, usage, balance, management protocols, and changes in investment projects. It also contains accountant verification and sponsor opinions on compliance with regulatory guidelines. The document is lengthy (9475 characters) and contains substantive financial data and analysis related to fundraising and fund usage, not just an announcement or summary. This matches the description of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes. It is not an Annual Report, Interim Report, or Earnings Release, as it focuses specifically on fundraising and fund usage. Therefore, the appropriate classification is CAP with high confidence.
2024-04-28 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.